Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE) (RCT-IVVE)
A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events
Sponsor: McMaster University
A PHASE4 clinical study on Heart Failure and Influenza, this trial is ongoing. The trial is conducted by McMaster University and has accumulated 8 data snapshots since 2016. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Nov 2018 — Jan 2021 [monthly]
Recruiting PHASE4
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE4
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE4
-
Aug 2017 — May 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE4
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- McMaster University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abu Dhabi, United Arab Emirates , Beijing, China , Beirut, Lebanon , Douala, Cameroon , Kampala, Uganda , Kano, Nigeria , Khartoum, Sudan , Lusaka, Zambia , Manila, Philippines , Maputo, Mozambique and 3 more locations